Formulation: A solid
Formal Name: N-[cis-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide
Purity: ≥98%
Formula Markup: C14H21N5O2S
Formula Weight: 323,4
Shelf life (days): 1460
CAS Number: 1622902-68-4
Notes: Abrocitinib is a JAK1 inhibitor (IC50 = 0.029 µM).{62536} It is selective for JAK1 over JAK2, JAK3, and TYK2 (IC50s = 0.803, >10, and 1.253 µM, respectively) and a panel of 40 kinases at 1 µM. Abrocitinib inhibits IFN-α-, IL-21-, or IL-27-induced phosphorylation of STAT3 (IC50s = 0.189, 0.511, and 0.271 µM, respectively) and IFN-γ-induced phosphorylation of STAT1 (IC50 = 0.163 µM) in isolated human whole blood. It reduces paw edema in a rat model of adjuvant-induced arthritis when administered at doses of 1, 5, and 15 mg/kg. Formulations containing abrocitinib have been used in the treatment of atopic dermatitis.
English
Deutsch
